Drugs Made In America Acquisition Corp. (the "Company") reported its financial results for the third quarter of 2025, revealing a net income of $2.18 million for the three months ending September 30, 2025, compared to a net loss of $144,928 for the same period in 2024. For the nine months ended September 30, 2025, the Company recorded a net income of $5.73 million, significantly improving from a loss of $199,859 during the initial period from May 23, 2024, through September 30, 2024. The increase in net income is attributed primarily to interest earned on cash and investments held in the trust account, which amounted to $2.45 million for the third quarter and $6.45 million for the nine-month period.
The Company’s total assets as of September 30, 2025, were reported at $237.63 million, a substantial increase from $550,824 at the end of 2024. This growth is largely due to the funds raised during the Initial Public Offering (IPO) and subsequent over-allotment option, which generated gross proceeds of $230 million. The Company has 33,517,143 ordinary shares outstanding, including 23 million shares subject to possible redemption at a value of $10.33 per share. The total liabilities stood at $7.36 million, reflecting an increase from $795,669 at the end of 2024, primarily due to accrued offering costs and a deferred underwriting fee payable.
In terms of strategic developments, the Company completed its IPO on January 29, 2025, selling 20 million units at $10.00 each, followed by an additional 3 million units through an over-allotment option exercised on February 18, 2025. The proceeds from these offerings have been placed in a trust account, which will be utilized for a future business combination. The Company has not yet identified a target for acquisition but intends to focus on opportunities within the pharmaceutical industry. As of the reporting date, the Company had not commenced any operations and does not expect to generate operating revenues until after completing a business combination.
Operationally, the Company has incurred general and administrative costs of $263,703 for the third quarter and $726,547 for the nine-month period, reflecting the costs associated with being a public entity and preparing for its initial business combination. The Company’s cash position at the end of the reporting period was $717, indicating a working capital deficit of $428,415. The management has expressed concerns regarding the Company’s ability to continue as a going concern, given the mandatory liquidation timeline and the need to complete a business combination by April 29, 2026, with potential extensions available.
Looking ahead, the Company plans to utilize the funds in the trust account to finance its initial business combination and is actively seeking suitable acquisition targets. However, there is no assurance that the Company will successfully complete a business combination within the specified timeframe. The management has indicated that they will continue to assess opportunities and may require additional financing to meet operational needs or to facilitate a business combination, which could involve issuing new securities or incurring debt.
About Drugs Made In America Acquisition Corp.
A special purpose acquisition company (SPAC) incorporated in the Cayman Islands, Drugs Made in America Acquisition Corp. aims to identify and acquire a leading pharmaceutical business in the United States. Its focus is on building a fully integrated, domestic drug manufacturing platform to enhance supply chain resilience, reduce reliance on foreign sources, and address drug shortages. The company leverages industry expertise, strategic acquisitions, and public market access to create value in the pharmaceutical sector.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.